PropertyValue
is ?:annotates of
?:authorAffiliation
  • [\'Division of Outcomes and Value Research, John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, New Jersey, United States of America.\', \'Berry Consultants LLC, Austin, Texas, United States of America.\', \'M.D. Anderson Cancer Center of the University of Texas, Houston, Texas, United States of America.\', \'COTA, Boston, Massachusetts, United States of America.\', \'John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, New Jersey, United States of America.\', \'Hackensack Meridian Health, Hackensack New Jersey and Hackensack Meridian School of Medicine, Nutley, New Jersey, United States of America.\']
?:citedBy
  • -1
?:creator
?:doi
  • 10.1371/journal.pone.0237693
?:doi
?:hasPublicationType
?:journal
  • PloS one
is ?:pmid of
?:pmid
?:pmid
  • 32790733
?:publication_isRelatedTo_Disease
?:rankingScore_SJR
  • 1.164
?:rankingScore_hIndex
  • 241
is ?:relation_isRelatedTo_publication of
?:title
  • Hydroxychloroquine and tocilizumab therapy in COVID-19 patients-An observational study.
?:type
?:year
  • 2020

Metadata

Anon_0  
expand all